Trupanion, Inc. (NASDAQ:TRUP - Get Free Report) Director Howard Rubin sold 30,000 shares of the company's stock in a transaction on Monday, November 9th. The shares were sold at an average price of $35.23, for a total value of $1,056,900.00. Following the transaction, the director directly owned 203,288 shares in the company, valued at $7,161,836.24. The trade was a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Trupanion Stock Down 0.2%
Trupanion stock traded down $0.06 during mid-day trading on Thursday, hitting $34.30. The company's stock had a trading volume of 241,698 shares, compared to its average volume of 463,336. Trupanion, Inc. has a 52-week low of $21.16 and a 52-week high of $39.61. The company has a market cap of $1.48 billion, a PE ratio of 56.33, a price-to-earnings-growth ratio of 1.59 and a beta of 1.27. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.74 and a quick ratio of 1.74. The firm's 50 day moving average is $27.61 and its 200 day moving average is $26.73.
Trupanion (NASDAQ:TRUP - Get Free Report) last released its earnings results on Thursday, November 5th. The financial services provider reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.04. The company had revenue of $405.59 million for the quarter, compared to analysts' expectations of $402.53 million. Trupanion had a return on equity of 6.71% and a net margin of 1.71%. During the same quarter in the previous year, the business posted $0.13 EPS. On average, analysts anticipate that Trupanion, Inc. will post 0.68 earnings per share for the current year.
Analysts Set New Price Targets
TRUP has been the subject of a number of research analyst reports. Stifel Nicolaus increased their target price on shares of Trupanion from $29.00 to $34.00 and gave the stock a "hold" rating in a research report on Monday. Zacks Research lowered shares of Trupanion from a "strong-buy" rating to a "hold" rating in a research note on Monday, August 24th. Weiss Ratings upgraded shares of Trupanion from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, September 29th. Atlantic Securities set a $42.00 price target on shares of Trupanion in a research note on Wednesday, July 15th. Finally, Piper Sandler downgraded shares of Trupanion from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $45.00 to $32.00 in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $40.00.
View Our Latest Stock Report on TRUP
Institutional Investors Weigh In On Trupanion
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in Trupanion in the second quarter worth approximately $134,774,000. Bank of America Corp DE bought a new position in Trupanion during the second quarter valued at approximately $14,262,000. Renaissancere Holdings Ltd. acquired a new stake in Trupanion in the second quarter valued at approximately $6,514,510. Bank of New York Mellon Corp acquired a new stake in Trupanion in the second quarter valued at approximately $4,631,000. Finally, Kopion Asset Management LLC lifted its stake in Trupanion by 30.9% in the second quarter. Kopion Asset Management LLC now owns 522,999 shares of the financial services provider's stock valued at $12,955,000 after acquiring an additional 123,308 shares during the last quarter.
Trupanion Company Profile
(
Get Free Report)
Trupanion provides medical insurance for cats and dogs, offering coverage for eligible veterinary care. Its products are designed to help pet owners manage unexpected costs from illnesses and injuries, subject to policy terms and exclusions. The company also provides software and payment services that enable participating veterinary practices to submit claims and receive payments directly, reducing the need for customers to pay covered costs upfront and seek reimbursement. Founded in 2000 and headquartered in Seattle, Trupanion serves customers in the United States and Canada.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Trupanion, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Trupanion wasn't on the list.
While Trupanion currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.